We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...

In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that ...

Barclays analyst Gena Wang maintained a Buy rating on Bluebird Bio (BLUE – Research Report) yesterday and set a price target of $40.00. Discover the latest stocks recommended by top Wall Street ...

Pre-Market: 8:12:05 a.m. EST Loading Chart for BLUE ...

Barclays analyst Gena Wang raised the firm’s price target on Bluebird Bio (BLUE) to $40 from $2 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect ...

根据最近的SEC文件显示，bluebird bio, Inc.（纳斯达克股票代码：BLUE）的首席医疗官Richard A.

根据提交给美国证券交易委员会的文件显示，bluebird bio, Inc.（纳斯达克股票代码：BLUE）总裁兼首席执行官Andrew Obenshain最近出售了部分公司持股。Obenshain以每股9.24美元的价格出售了140股普通股，总计约1,293美元。根据 InvestingPro 的数据，该公司股票目前交易价格为8.46美元，过去一年下跌近70%，显示出显著的波动性。